Get the Stockscreener App
3.09
17.94%
0.47
After Hours:
3.05
-0.04
-1.29%
Akoya Biosciences Inc stock is traded at $3.09, with a volume of 147.08K.
It is up +17.94% in the last 24 hours and up +11.15% over the past month.
Akoya Biosciences Inc is a life sciences technology company. It is delivering spatial biology solutions focused on transforming discovery, clinical research and diagnostics. Its PhenoCycler (formerly CODEX) and PhenoImager (formerly Phenoptics) platforms, reagents, software, and services, It offer end-to-end solutions to perform tissue analysis and spatial phenotyping across the full continuum from discovery through translational and clinical research and diagnostics.
See More
Previous Close:
$2.62
Open:
$2.6
24h Volume:
147.08K
Relative Volume:
1.03
Market Cap:
$137.11M
Revenue:
$96.63M
Net Income/Loss:
$-63.32M
P/E Ratio:
-1.5685
EPS:
-1.97
Net Cash Flow:
$-54.55M
1W Performance:
+8.42%
1M Performance:
+11.15%
6M Performance:
-23.51%
1Y Performance:
-21.97%
1-Day Range:
$2.5974
$3.10
1-Week Range:
$2.50
$3.10
52-Week Range:
$1.88
$6.31
Akoya Biosciences Inc Stock (AKYA) Company Profile
Name
Akoya Biosciences Inc
Sector
Industry
Phone
855.896.8401
Address
100 CAMPUS DRIVE, MARLBOROUGH
Akoya Biosciences Inc Stock (AKYA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| Feb-02-23 | Initiated | UBS | Buy |
| Nov-03-22 | Initiated | CapitalOne | Overweight |
| Oct-06-22 | Initiated | Stephens | Overweight |
| Jun-22-22 | Initiated | BTIG Research | Buy |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| May-11-21 | Initiated | Canaccord Genuity | Buy |
| May-11-21 | Initiated | JP Morgan | Overweight |
| May-11-21 | Initiated | Morgan Stanley | Overweight |
| May-11-21 | Initiated | Piper Sandler | Overweight |
View All
Akoya Biosciences Inc Stock (AKYA) Latest News
Akoya Biosciences Unveils a New Era in Spatial Content - GlobeNewswire
Akoya Biosciences Unveils a New Era in Spatial Content Innovation with the PhenoCode™ Discovery IO60 and Mouse FFPE IO Panel - StockTitan
Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace
Akoya Biosciences, Inc. (NASDAQ:AKYA) Sees Significant Decrease in Short Interest - MarketBeat
Akoya Bioscience to Report Third Quarter 2024 Financial Results on November 14, 2024 - StockTitan
BTIG Downgrades Akoya Biosciences (AKYA) - MSN
Akoya Biosciences, Inc. (NASDAQ:AKYA) Receives $6.56 Consensus Price Target from Brokerages - MarketBeat
Akoya Biosciences (AKYA) Stock Price, News & Analysis - MarketBeat
Akoya Biosciences Inc (AKYA) Stock: A Year of Highs and Lows in the Market - The InvestChronicle
Akoya Biosciences, Inc. (NASDAQ:AKYA) Stock Rockets 36% But Many Are Still Ignoring The Company - Simply Wall St
Akoya Biosciences joins UK cancer research initiative By Investing.com - Investing.com South Africa
Akoya Biosciences joins UK cancer research initiative - Investing.com India
Akoya’s Leading Spatial Proteomics Platforms Selected for - GlobeNewswire
Akoya's Leading Spatial Proteomics Platforms Selected for Use by Ground-Breaking UK-Based MANIFEST Consortium to Revolutionize Cancer Immunotherapy - The Manila Times
Akoya's Leading Spatial Proteomics Platforms Selected for Use by Uk-Based Manifest Consortium to Revolutionize Cancer Immunotherapy - Marketscreener.com
IPO Alert: Akoya Biosciences - RTTNews
Akoya Biosciences appoints new chairman By Investing.com - Investing.com South Africa
Akoya Biosciences Appoints Scott Mendel as Chairman of the Board of Directors - citybiz
Akoya Biosciences Announces Scott Mendel as Chairman of the Board of Directors - ForexTV.com
Akoya Biosciences appoints new chairman - Investing.com
Akoya Biosciences names Scott Mendel as new board chairman By Investing.com - Investing.com Australia
Akoya Biosciences names Scott Mendel as new board chairman - Investing.com
Spatial Proteomics Market Size, Share, Growth Report, 2030 - Grand View Research
Akoya Biosciences, Inc. (NASDAQ:AKYA) Sees Large Decline in Short Interest - MarketBeat
Wall Street SWOT: Akoya Biosciences stock faces headwinds amid spatial proteomics growth By Investing.com - Investing.com South Africa
Wall Street SWOT: Akoya Biosciences stock faces headwinds amid spatial proteomics growth - Investing.com
Caxton Associates LP Takes $2.23 Million Position in American International Group, Inc. (NYSE:AIG) - Defense World
Global Spatial Omics Market Projected to Reach $ 424.2 Million by 2032, Growing at 10.5% CAGR - 대구포스트
Brokerages Set Akoya Biosciences, Inc. (NASDAQ:AKYA) Target Price at $6.56 - MarketBeat
Akoya Biosciences, Inc. (NASDAQ:AKYA) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Immunohistochemistry IHC Market Advancements Highlighted by Size, Share Analysis, Trends And Forecast 2024-... - WhaTech
Piper Sandler Maintains Akoya Biosciences (AKYA) Overweight Recommendation - MSN
Akoya Biosciences, Inc.'s (NASDAQ:AKYA) biggest owners are private equity firms who got richer after stock soared 18% last week - Simply Wall St
Akoya Biosciences, Inc. (NASDAQ:AKYA) Short Interest Up 6.3% in August - MarketBeat
Akoya Biosciences, Inc. (NASDAQ:AKYA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Spatial OMICS Market Size, Growth Analysis | CAGR of 10.7% - Market.us
Europe, CIS & Africa Spatial Transcriptomics (Instruments, Consumables) Market Size, Share & Trends Analysis Report 2024-2030 - GlobeNewswire Inc.
Akoya Biosciences, Inc. (NASDAQ:AKYA) Sees Large Growth in Short Interest - Defense World
Akoya Biosciences, Inc. (NASDAQ:AKYA) Sees Large Increase in Short Interest - MarketBeat
Vanguard Group Inc. Has $6.82 Million Stock Position in Akoya Biosciences, Inc. (NASDAQ:AKYA) - Defense World
Akoya Biosciences (NASDAQ:AKYA) Price Target Lowered to $4.00 at Piper Sandler - Defense World
Akoya Biosciences, Inc. (NASDAQ:AKYA) Just Reported, And Analysts Assigned A US$5.42 Price Target - Simply Wall St
FY2024 EPS Estimates for Akoya Biosciences, Inc. Raised by Capital One Financial (NASDAQ:AKYA) - MarketBeat
Capital One Financial Research Analysts Boost Earnings Estimates for Akoya Biosciences, Inc. (NASDAQ:AKYA) - Defense World
Akoya Biosciences Second Quarter 2024 Earnings: Revenues Disappoint - Yahoo Finance
Closing Figures: Akoya Biosciences Inc (AKYA)’s Negative Finish at 2.01, Down -6.51 - The Dwinnex
Insiders Give Up US$52k As Akoya Biosciences Stock Drops To US$2.01 - Simply Wall St
JP Morgan Downgrades Akoya Biosciences (AKYA) - MSN
Akoya Biosciences (NASDAQ:AKYA) Price Target Lowered to $7.00 at Craig Hallum - Defense World
Akoya Biosciences (NASDAQ:AKYA) Price Target Cut to $7.00 by Analysts at Craig Hallum - MarketBeat
Akoya Biosciences (NASDAQ:AKYA) Releases Quarterly Earnings Results, Hits Expectations - MarketBeat
Akoya Biosciences Inc Stock (AKYA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Akoya Biosciences Inc Stock (AKYA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| McKelligon Brian | President and CEO |
Jun 11 '24 |
Sale |
2.08 |
7,500 |
15,630 |
224,733 |
| McKelligon Brian | President and CEO |
Jun 06 '24 |
Option Exercise |
0.30 |
7,500 |
2,272 |
232,233 |
| McKelligon Brian | President and CEO |
Jun 06 '24 |
Sale |
2.01 |
7,500 |
15,064 |
224,733 |
| McKelligon Brian | President and CEO |
Mar 20 '24 |
Option Exercise |
0.30 |
7,500 |
2,272 |
239,368 |
| McKelligon Brian | President and CEO |
Mar 20 '24 |
Sale |
4.97 |
7,500 |
37,243 |
231,868 |
| McKelligon Brian | President and CEO |
Mar 13 '24 |
Sale |
4.94 |
7,500 |
37,035 |
224,368 |
| McKelligon Brian | President and CEO |
Dec 19 '23 |
Option Exercise |
0.30 |
7,500 |
2,272 |
160,063 |
| McKelligon Brian | President and CEO |
Dec 19 '23 |
Sale |
4.48 |
7,500 |
33,566 |
152,563 |
| McKelligon Brian | President and CEO |
Dec 12 '23 |
Option Exercise |
0.30 |
7,500 |
2,272 |
160,063 |
| McKelligon Brian | President and CEO |
Dec 12 '23 |
Sale |
4.25 |
7,500 |
31,871 |
152,563 |
0.98%
5.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):